Study #2023-0998
A phase 1, first-in-human study of CUSP06, a cadherin- 6 (CDH6)-directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
CUSP06
Description
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer, Solid Tumor
Study phase:
Phase I
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-577-0738
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.